Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Carcinoma ductal de parótida HER2+: estrategia terapéutica ante la progresión a varias líneas de quimioterapia. Evidencia disponible

Autor: Losada Vila, Beatriz, Caballero Perea, Begoña R., Pantín González, María C., Letéllez Fernández, Javier, Gutiérrez Abad, David

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9eecd480da22bc26ab3a5cdb7d0e810f
https://hdl.handle.net/20.500.12530/54359

P-297 - Efficacy and toxicity results of FOLFIRI-Aflibercept in advanced colorectal cancer (CRCm) in “real life”, retrospective study. Prognostic factors and specific populations.

Autor: Fernandez Montes, Ana, Carlos López, López, Carmona, Alberto, Paez, David, Lopez Muñoz Ana, María, Gutierrez Abad, David, Carmen Castañón, López, Maria, del Carmen López Doldán, Eva Martínez, de Castro, Manuel Sánchez, Cánovas, Tobeña, Maria, Beatriz Llorente, Ayala, Juez Martel, Ignacio, Mariana López, Flores, García-Paredes, Beatriz, Cacho Lanvin, Diego, Salgado, Mercedes, Virgili, Anna, Beatriz Arbeola, Esparza

Publikováno v: In Annals of Oncology June 2017 28 Supplement 3:iii103-iii103

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients.

Autor: Pena-Couso L; Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Ercibengoa M; Respiratory Infection and Antimicrobial Resistance Group, Infectious Diseases Area, BioDonostia; Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, San Sebastian, Spain., Mercadillo F; Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Gómez-Sánchez D; Hereditary Cancer Laboratory, 12 de Octubre University Hospital, i+12 Research Institute, Madrid, Spain.; Clinical and Translational Lung Cancer Research Unit, i+12 Research Institute and Biomedical Research Networking Center in Oncology (CIBERONC), Madrid, Spain., Inglada-Pérez L; Biostatistics Unit, Statistics and Operational Research Department, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain., Santos M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Lanillos J; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Gutiérrez-Abad D; Medical Oncology Service, University Hospital of Fuenlabrada, Fuenlabrada, Spain., Hernández A; Dermatology Service, University Hospital of Fuenlabrada, Fuenlabrada, Spain., Carbonell P; Biochemistry and Clinical Genetics Centre, Virgen Arrixaca University Hospital, Murcia, Spain., Letón R; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Robledo M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Rare Diseases Networking Biomedical Research Centre (CIBERER), Madrid, Spain., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Rare Diseases Networking Biomedical Research Centre (CIBERER), Madrid, Spain., Perea J; Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; Health Research Institute-Fundación Jiménez Díaz University Hospital, Madrid, Spain., Urioste M; Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. murioste@cnio.es.

Publikováno v: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2022 Feb 28; Vol. 17 (1), pp. 85. Date of Electronic Publication: 2022 Feb 28.